نتایج جستجو برای: high dose cytarabine

تعداد نتایج: 2292508  

2017
Brandi Anders Lauren Veltri Abraham S Kanate Alexandra Shillingburg Nilay Shah Michael Craig Aaron Cumpston

Relapsed/refractory acute myeloid leukemia (RR-AML) is associated with poor prognosis and long-term disease-free survival requires allogeneic hematopoietic cell transplantation (allo-HCT). Limited data exists, regarding the optimal regimen to obtain remission prior to allo-HCT. Single agent high-dose cytarabine (10-12 doses administered every 12 hours) has been previously used as induction ther...

Journal: :Blood 1996
J F Bishop J P Matthews G A Young J Szer A Gillett D Joshua K Bradstock A Enno M M Wolf R Fox R Cobcroft R Herrmann M Van Der Weyden R M Lowenthal F Page O M Garson S Juneja

High-dose cytarabine (ara-c) may overcome cytarabine resistance in leukemic blasts. It has been used as a successful salvage and in postremission therapy but not as initial induction treatment. Patients aged 15 to 60 years, presenting with newly diagnosed acute myeloid leukemia (AML) were randomized to receive either high-dose cytarabine, 3 g/m2 12 hourly on days 1, 3, 5, and 7 for 8 doses, dau...

2017
Fatos Dilan Koseoglu Gulnur Gorgun Feray Gulec Uyaroglu Cagatay Arslan

High dose (1-3 g/m2 every 12 hours) cytosine arabinoside (ara-C) is a potent treatment for acute myeloid leukemia (AML) in consolidation therapy which is well known that improves the diseasefree-survival (DFS). Cerebellar neurotoxicity is well-recognized complication following high-dose cytosine arabinoside (≥3 g/m2 every 12 hours), but peripheral neurotoxicity is not common as well. This poten...

Journal: :Leukemia & lymphoma 2010
Lucy A Godley Uchenna O Njiaju Margaret Green Howard Weiner Shang Lin Olatoyosi Odenike Elizabeth S Rich Andrew Artz Koen Van Besien Christopher K Daugherty Yanming Zhang Michelle M Le Beau Wendy Stock Richard A Larson

Few clinical protocols have focused on patients with therapy-related myeloid neoplasms (t-MN). Therefore, we enrolled 32 patients with previously untreated t-MN on a clinical trial testing the effectiveness of a unified induction regimen of high-dose cytarabine and mitoxantrone. The complete remission (CR) rate was 66% (95% CI 47-81%) and the partial remission (PR) rate was 16% (95% CI 5-33%), ...

Journal: :Haematologica 2010
Wendy Deenik Jeroen J W M Janssen Bronno van der Holt Gregor E G Verhoef Willem M Smit Marie José Kersten Simon M G J Daenen Leo F Verdonck Augustin Ferrant Anton V M B Schattenberg Pieter Sonneveld Marinus van Marwijk Kooy Shulamit Wittebol Roelof Willemze Pierre W Wijermans H Berna Beverloo Bob Löwenberg Peter J M Valk Gert J Ossenkoppele Jan J Cornelissen

BACKGROUND In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-51 study. DESIGN AND METHODS Having reported feasibility previously, we hereby report the efficacy of escalated imatinib (200 mg, 400 mg, 600 mg o...

Journal: :Cancer 2008
Stefan Faderl Alessandra Ferrajoli William Wierda Xuelin Huang Srdan Verstovsek Farhad Ravandi Zeev Estrov Gautam Borthakur Monica Kwari Hagop M Kantarjian

BACKGROUND Outcome of patients with relapsed acute myeloid leukemia (AML) remains unsatisfactory. Clofarabine is a nucleoside analog with activity in adult AML. Combinations with cytarabine in AML are feasible and effective. Idarubicin is another active AML drug, which has not yet been tested with clofarabine. METHODS The authors therefore designed a phase I study of clofarabine +/- cytarabin...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید